

REMARKS

Claims 1-8 are pending. Applicant has amended claims 1-3 to be commensurate in scope with the elected subject matter. Claims 4-8 are dependent on these amended claims. Applicant expressly reserves the right to file divisional applications on the non-elected subject matter.

Claims 9-15 are herein designated as withdrawn to comply with the restriction requirement. Nevertheless, Applicants submit that once the compounds of the present invention are found to be novel, then the other Groups defined by the Examiner that contain those compounds should also be found to be novel and rejoined. Applicants note the statement on page 3 of the Office Action wherein it is stated that "rejoinder of product claims and method of preparation commensurate in scope with the allowed product claims *will occur* following a finding that the product claims are allowable".

Finally, Applicants request confirmation that the amendment submitted February 5, 2007, has been entered.

Respectfully submitted,



Barbara E. Kurys, Reg. No.: 34,650
Attorney/Agent for Applicant

sanofi-aventis Inc. LLC
U.S. Patent Operations
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-**2965**
Telefax (908) 231-2626

sanofi-aventis Docket No. DEAV2003/0019 US NP